Big things are happening in oncology at the moment. Considering all stages of clinical development, there are thought to be up to 8,000 anticancer candidates be 12 November 2018
As far as PARP inhibitors are concerned, AstraZeneca stole the show at the annual congress of ESMO this month, with the SOLO-1 trial of Lynparza (olaparib) show 9 November 2018
At the annual congress of the European Society of Medical Oncology (ESMO) this week, AstraZeneca’s Susan Galbraith told The Pharma Letter the firm was “very pro 25 October 2018
At a late-breaking session of Saturday’s Presidential Symposium, Novartis revealed striking breast cancer data from the Phase III SOLAR-1 trial of its PI3K bloc 23 October 2018
Merck & Co has presented striking data in head and neck cancer which, in line with the theme of this year’s ESMO congress, demonstrate the growing breadth of in 22 October 2018
In the first-line kidney cancer setting, Germany’s Merck KGaA has thrown its hat firmly into the ring, with strong data from the JAVELIN Renal 101 trial showing 22 October 2018
For the first time, an immuno-oncology therapy has been shown to be effective against breast cancer, new data highlighted at the annual ESMO congress have shown 22 October 2018
East Coast, USA-based Loxo Oncology and Germany’s Bayer have announced clinical data for their investigational TRK blocker larotrectinib at the annual congress 21 October 2018
While PARP blocker rivals AstraZeneca and Tesaro chase the prize of a first-line ovarian cancer indication, Clovis Oncology is highlighting what it sees as prom 19 October 2018
A new study has found significant variations between European countries in the time it takes for reimbursement decisions to be made on new cancer drugs, with so 19 October 2018
Merck has revealed positive data from the Phase III KEYNOTE-426 trial of Keytruda (pembrolizumab) plus Inlyta (axitinib) in the first-line treatment of advanced 19 October 2018
Something like 20,000 conference delegates are gathered in Munich for the start of what promises to be another important meeting of the European Society of Medi 19 October 2018
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.